A Multicenter, Phase 1/2 Study of Ramucirumab Plus Nivolumab as Second-line Therapy in Participants With Gastric or GEJ Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 18 Jan 2018
At a glance
- Drugs Nivolumab (Primary) ; Ramucirumab (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- 16 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 18 Sep 2017 Planned End Date changed from 31 Dec 2018 to 1 Jan 2019.
- 18 Sep 2017 Planned primary completion date changed from 1 Jun 2019 to 1 Jan 2018.